AstraZeneca ended a Phase 3 trial of volrustomig after an interim data check indicated it was unlikely to meet survival endpoints when combined with chemotherapy. The decision adds to a series of pipeline setbacks for the company as investors weigh execution and translation risks across oncology. A separate report indicated AstraZeneca has also stopped another lung cancer study involving volrustomig based on interim efficacy comparisons to Keytruda (pembrolizumab), further narrowing the strategic space for bispecific replacement approaches. —